サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1587563

特発性肺線維症治療の市場規模、シェア、動向分析レポート：薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Pirfenidone, Nintedanib), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.26円
特発性肺線維症治療の市場規模、シェア、動向分析レポート：薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年10月10日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

特発性肺線維症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、特発性肺線維症治療の世界市場規模は2025年から2030年にかけてCAGR 6.8％を記録し、2030年までに54億6,000万米ドルに達すると予測されています。

企業による研究開発イニシアチブの増加と喫煙人口の急増が成長を後押しすると予測されています。

新規のメカニズムを持つ製品を開発するためにメーカーが行っているイニシアチブの増加は、IPF治療市場の成長を促進すると予測されています。例えば、ファイブロジェン社は現在、結合組織成長因子を標的とするモノクローナル抗体であるパムレブルマブを開発中です。パムレブルマブの第III相試験は2019年前半に開始される予定です。同薬は食品医薬品局（FDA）からファスト・トラック指定を受けています。

高齢化は、ヘルスケア部門を含むほぼすべての部門に社会的、経済的、政治的に広範囲な影響を及ぼすと予想されます。老人人口の増加に伴う結果として、長期介護を必要とする様々な病状の発生率が増加します。さらに、中国や日本など未開拓の機会が多い国々における老人人口の増加が、予測期間中の市場成長を促進すると予想されます。

喫煙人口の激増は市場成長に好影響を与えそうな主要促進要因の一つです。米国FDAおよび疾病対策予防センター（CDC）によると、2018年には360万人以上の高校生および中学生が既存の電子タバコユーザーでした。この数は昨年から150万人増加しました。電子タバコの普及はIPFの発症につながると予想されています。

特発性肺線維症治療市場レポートハイライト：

  • ピルフェニドンが市場を独占し、2024年のシェアは43.0%。
  • 経口投与薬が市場をリードし、2024年の売上シェアは69.3%。ピルフェニドンとニンテダニブは注射療法に比べて患者のコンプライアンスを高める。
  • 病院薬局が2024年に62.9％の売上高シェアで最大を占めました。病院はIPFの正確な診断とモニタリングのための高度な診断ツールを備えており、タイムリーな治療開始が容易だからです。
  • 2024年、米国がIPFの市場浸透度と認知度の高さからリード。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 特発性肺線維症治療市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析

第4章 特発性肺線維症治療市場：薬剤クラスのビジネス分析

  • 薬物クラス市場シェア、2024年および2030年
  • 薬物クラスセグメントダッシュボード
  • 市場規模と予測および動向分析、薬剤クラス別、2018～2030年
  • ピルフェニドン
  • ニンテダニブ
  • インターフェロンガンマト1b
  • その他

第5章 特発性肺線維症治療市場：投与経路のビジネス分析

  • 投与経路の市場シェア、2024年と2030年
  • 投与経路セグメントダッシュボード
  • 市場規模と予測および動向分析、投与経路別、2018～2030年
  • 経口
  • 注射

第6章 特発性肺線維症治療市場：流通チャネルのビジネス分析

  • 流通チャネル市場シェア、2024年および2030年
  • 流通チャネルセグメントダッシュボード
  • 市場規模と予測および動向分析、流通チャネル別、2018～2030年
  • 病院薬局
  • 小売薬局
  • その他

第7章 特発性肺線維症治療市場：薬剤クラス別の地域別推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 国別、2018年-2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018年-2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018年-2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018年-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • F. Hoffmann-La Roche Ltd
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Medicinova, Inc
    • Merck &Co., Inc.
    • Galapagos NV
    • Novartis AG
    • Fibrogen, Inc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global idiopathic pulmonary fibrosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 Global idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 North America idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 U.S. idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 13 U.S. Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 Canada idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 Canada idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Mexico idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Europe idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 UK idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 UK Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 Germany idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 28 Germany idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29 Germany idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 France idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 France Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Italy idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Italy idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 37 Spain idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 38 Spain idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Norway idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Norway Idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 43 Denmark idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Denmark idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Sweden idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Sweden idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Japan idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Japan idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54 Japan idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 China idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 China idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 China idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 India idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 India idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Australia idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Australia idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Australia idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 65 South Korea idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 South Korea idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Thailand idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 Thailand idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 72 Latin America idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Latin America idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 75 Brazil idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Brazil idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 78 Argentina idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 79 Argentina idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Idiopathic pulmonary fibrosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 South Africa idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 South Africa idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 91 UAE idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 92 UAE idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait idiopathic pulmonary fibrosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 94 Kuwait idiopathic pulmonary fibrosis treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 Kuwait idiopathic pulmonary fibrosis treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Idiopathic pulmonary fibrosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class and route of administration outlook (USD Million)
  • Fig. 10 Distribution channel outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Idiopathic pulmonary fibrosis treatment market dynamics
  • Fig. 13 Idiopathic pulmonary fibrosis treatment market: Porter's five forces analysis
  • Fig. 14 Idiopathic pulmonary fibrosis treatment market: PESTLE analysis
  • Fig. 15 Idiopathic pulmonary fibrosis treatment market: Drug class segment dashboard
  • Fig. 16 Idiopathic pulmonary fibrosis treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 17 Pirfenidone market, 2018 - 2030 (USD Million)
  • Fig. 18 Nintedanib market, 2018 - 2030 (USD Million)
  • Fig. 19 Interferon Gammato1b market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 Idiopathic pulmonary fibrosis treatment market: Route of administration segment dashboard
  • Fig. 22 Idiopathic pulmonary fibrosis treatment market: Route of administration market share analysis, 2024 & 2030
  • Fig. 23 Oral market, 2018 - 2030 (USD Million)
  • Fig. 24 Injectable market, 2018 - 2030 (USD Million)
  • Fig. 25 Idiopathic pulmonary fibrosis treatment market: Distribution channel segment dashboard
  • Fig. 26 Idiopathic pulmonary fibrosis treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 27 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 28 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Idiopathic pulmonary fibrosis treatment market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 France country dynamics
  • Fig. 46 France idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 China country dynamics
  • Fig. 61 China idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 Latin America idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 MEA idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait idiopathic pulmonary fibrosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework
目次
Product Code: GVR-3-68038-119-1

Idiopathic Pulmonary Fibrosis Treatment Market Growth & Trends:

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 5.46 billion by 2030, registering a CAGR of 6.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing R&D initiatives undertaken by companies and surge in cigarette smoking population are anticipated to boost the growth.

Rise in the initiatives undertaken by manufacturers to develop products with novel mechanisms is anticipated to fuel the IPF treatment market growth. For instance, FibroGen, Inc., is currently developing a drug, pamrevlumab - a monoclonal antibody that targets the connective tissue growth factor. The phase III trials of pamrevlumab are expected to be initiated in the first half of 2019. The drug has received fast track designation from the Food and Drug Administration (FDA).

An aging population can be expected to have far-reaching social, economic, and political implications on nearly all the sectors including the healthcare sector. An associated consequence of an increase in the geriatric population will be an increase in the incidences of various medical conditions requiring long-term care. Moreover, the growing geriatric population base in countries with large untapped opportunities such as China and Japan is anticipated to drive the market growth during the forecast period.

The dramatic increase in cigarette smoking population is one of the major drivers likely to have a positive impact on market growth. According to the U.S. FDA and Centers for Disease Control and Prevention (CDC), in 2018, more than 3.6 million high and middle school students were existing e-cigarette users. The number increased by 1.5 million since the last year. The uptake in the use of e-cigarette is expected to lead to the incidence of IPF.

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights:

  • Pirfenidone dominated the market and accounted for a share of 43.0% in 2024.
  • Orally administered medications led the market with a revenue share of 69.3% in 2024. Pirfenidone and nintedanib enhance patient compliance compared to injectable therapies.
  • Hospital pharmacies held the largest revenue share 62.9% in 2024, as hospitals are equipped with advanced diagnostic tools for accurate IPF diagnosis and monitoring, facilitating timely treatment initiation.
  • U.S. led in 2024 due to high market penetration and high awareness pertaining to IPF

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Idiopathic Pulmonary Fibrosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Idiopathic Pulmonary Fibrosis Treatment Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Pirfenidone
    • 4.4.1. Pirfenidone Market, 2018 - 2030 (USD Million)
  • 4.5. Nintedanib
    • 4.5.1. Nintedanib Market, 2018 - 2030 (USD Million)
  • 4.6. Interferon Gammato1b
    • 4.6.1. Interferon Gammato1b Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Idiopathic Pulmonary Fibrosis Treatment Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 5.5. Injectable
    • 5.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 6. Idiopathic Pulmonary Fibrosis Treatment Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Idiopathic Pulmonary Fibrosis Treatment Market: Regional Estimates & Trend Analysis by Drug Class, Route Of Administration, and Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Idiopathic Pulmonary Fibrosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. F. Hoffmann-La Roche Ltd
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Boehringer Ingelheim International GmbH
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Bristol-Myers Squibb Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Medicinova, Inc
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merck & Co., Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Galapagos NV
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Novartis AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Fibrogen, Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives